Novartis: positive data for breast cancer drug
(CercleFinance.com) - Novartis has announced positive top-line results from an interim analysis of NATALEE, a phase III trial evaluating its Kisqali (ribociclib), in combination with hormone therapy, in early HR+/HER2- breast cancer at risk of recurrence.
The Swiss healthcare group says that the independent data monitoring committee recommended stopping the trial early because the primary endpoint of invasive disease-free survival was met.
Kisqali plus hormone therapy significantly reduced the risk of recurrence compared to standard hormone therapy alone in the adjuvant setting, with a consistent benefit in patients with early stage II and III breast cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.